Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study | Synapse
April 27, 2021Open Access
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Key Points
Key points are not available for this paper at this time.
Abstract
King's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute.